Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.46 |
| ▸ | CA1 | P00915 | 11/20 | 0.46 |
| ▸ | CA9 | Q16790 | 10/20 | 0.46 |
| ▸ | CA12 | O43570 | 8/20 | 0.46 |
| ▸ | CA5A | P35218 | 6/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.46 |
| ▸ | CA7 | P43166 | 5/20 | 0.46 |
| ▸ | CA6 | P23280 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20610117 | 0.77 | CA2 (0.44) | CA2CA1CA9CA12CA5A | |
| SCHEMBL1641567 | 0.77 | ENPP2 (0.37) | PTGS2 | |
| SCHEMBL25249974 | 0.75 | ALDH1A1 (0.44) | TDP1 | |
| SCHEMBL26597129 | 0.75 | CA2 (0.46) | CA2CA1CA9CA12CA5A | |
| SCHEMBL30566466 | 0.75 | PTGS2 (0.57) | CA2CA1CA9CA12CA5A | |
| SCHEMBL20610218 | 0.75 | CA1 (0.45) | CA2CA1CA9CA12CA5A | |
| SCHEMBL2118260 | 0.75 | PTGS2 (0.57) | CA2CA1CA9CA12CA5A | |
| SCHEMBL24221423 | 0.75 | CA2 (0.47) | CA2CA1CA9CA12CA5A | |
| SCHEMBL578844 | 0.75 | APLNR (0.44) | CA2CA1CA9CA12CA5A | |
| SCHEMBL17196316 | 0.73 | PSIP1 (0.44) | PTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719597-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246523-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| US-20220023277-A1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-2707102-B1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20120321563-A1 | Carbonic Anhydrase Targeting Agents and Methods of Using Same | VISEN MEDICAL, INC. | 2012-12-20 | — | — | US | disclosed |
| WO-2012154885-A2 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120321563-A1 | Carbonic Anhydrase Targeting Agents and Methods of Using Same | CA4, CA12, CA9 | CA2 4/4885CA1 7/4885CA9 3/4885 |
| US-20220023277-A1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | CA4, CA12, CA9 | CA2 4/4885CA1 7/4885CA9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.